Applying to Clinical Trial: An Open-Label Extension Study to Evaluate Long-Term Safety and Tolerability of RO7234292 (RG6042) in Huntington's Disease Participants Who Participated in Prior Roche and Genentech Sponsored Studies

Contact this trialFirst, we need to learn more about you.

Antisense Oligonucleotide

RO7234292 (RG6042) for Huntington's Disease

Recruiting2 awardsPhase 3

New York, New York

This trial will test the long-term safety of a drug called RO7234292 (RG6042) in people who have already participated in earlier studies for Huntington's disease. The drug is given through an injection into the spinal fluid periodically. The goal is to see if the drug remains safe and tolerable over a longer period. RO7234292 (RG6042) is being tested for its ability to target and reduce the production of the huntingtin protein, which is implicated in Huntington's disease.

Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.

We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our and .

Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.

By clicking start, you agree to our